Lifestyle interventions in nonalcoholic fatty liver disease
ZM Younossi, S Zelber-Sagi, L Henry… - Nature Reviews …, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) is a dynamic chronic liver disease that develops in
close association with metabolic irregularities. Between 2016 and 2019, the global …
close association with metabolic irregularities. Between 2016 and 2019, the global …
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver …
Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the
general population. The evidence base for the investigation and management of NAFLD is …
general population. The evidence base for the investigation and management of NAFLD is …
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
Background The reference standard for detecting non-alcoholic steatohepatitis (NASH) and
staging fibrosis—liver biopsy—is invasive and resource intensive. Non-invasive biomarkers …
staging fibrosis—liver biopsy—is invasive and resource intensive. Non-invasive biomarkers …
Placebo effect on progression and regression in NASH: evidence from a meta‐analysis
Methods A search was conducted to include NASH RCTs with placebo treatment arms.
Primary outcomes were (1) the resolution of NASH without worsening of fibrosis,(2) two …
Primary outcomes were (1) the resolution of NASH without worsening of fibrosis,(2) two …
[HTML][HTML] Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns
due to its inherent disadvantages of using exclusionary diagnostic criteria and the …
due to its inherent disadvantages of using exclusionary diagnostic criteria and the …
Ubiquitin-specific proteases (USPs) and metabolic disorders
H Kitamura - International Journal of Molecular Sciences, 2023 - mdpi.com
Ubiquitination and deubiquitination are reversible processes that modify the characteristics
of target proteins, including stability, intracellular localization, and enzymatic activity …
of target proteins, including stability, intracellular localization, and enzymatic activity …
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD)
poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD …
poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD …
A global action agenda for turning the tide on fatty liver disease
Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda
developed by care providers, clinical researchers, and public health and policy experts …
developed by care providers, clinical researchers, and public health and policy experts …
Towards precision medicine in non-alcoholic fatty liver disease
SM Francque - Reviews in Endocrine and Metabolic Disorders, 2023 - Springer
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) refers to the accumulation of lipid laden
vacuoles in hepatocytes, occurring in the context of visceral adiposity, insulin resistance and …
vacuoles in hepatocytes, occurring in the context of visceral adiposity, insulin resistance and …
Towards precision medicine in bariatric surgery prescription
SS Pereira, M Guimarães, MP Monteiro - Reviews in Endocrine and …, 2023 - Springer
Obesity is a complex, multifactorial and chronic disease. Bariatric surgery is a safe and
effective treatment intervention for obesity and obesity-related diseases. However, weight …
effective treatment intervention for obesity and obesity-related diseases. However, weight …